Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant

Inclusion Criteria: * Liver metastases from colo-rectal origin considered as resectable (as validated by a multidisciplinary committee with at least one senior hepatic surgeon) provided sufficient FRL volume * Percentage of FRL volume \< 30% * Age ≥ 18 years * General health status World Health Organisation 0,1 * Estimated life expectancy \> 3 months * Patients whose biological parameters are : * Platelets ≥100,000/mm3, * Polynuclear neutrophils ≥ 1000/mm3, * Hemoglobin≥ 9g/dL (even transfused patients can be included) * Creatininemia \< 1.5 times the normal value * Creatinine clearance \> 30 milliliters (mL)/min * Bilirubinemia ≤ 1,5 times the normal value * liver transaminases ≤ 5 times the normal value * prothrombin rate \> 70% * Reference liver CT-Scan or MRI done during the 30 days preceding PVE or LVD. * Written informed consent * National health insurance cover Exclusion criteria * Patient with cirrhosis * Presence of clinical ascites * Ongoing participation or participation within the 21 days prior to inclusion in the study in another therapeutic trial with an experimental drug * Serious non-stabilized disease, active uncontrolled infection or other serious underlying disorder likely to prevent the patient from receiving the treatment * Pregnancy (betaHCG positive), breast-feeding or the absence of effective contraception for women of child-bearing age * Contraindication for the MRI : Pacemaker or neurosensorial stimulator or implantable defibrilla…